Drug Discovery Targeting Drug-Resistant Bacteria

Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing. Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens. Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.

"This book provides quality information and is a good educational tool." --Doody

• 1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria